Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878148 | 1.00 | MAPT (0.47) | MAPTRAB9AGAANPC1LMNA | |
| SCHEMBL27937157 | 0.81 | FURIN (0.50) | MAPTRAB9AGAANPC1LMNA | |
| SCHEMBL11776061 | 0.80 | USP2 (0.54) | MAPTRAB9AGAANPC1TP53 | |
| SCHEMBL11776067 | 0.80 | USP2 (0.54) | MAPTRAB9AGAANPC1TP53 | |
| SCHEMBL12243287 | 0.80 | TP53 (0.68) | MAPTRAB9AGAANPC1LMNA | |
| SCHEMBL12296136 | 0.80 | TP53 (0.68) | MAPTRAB9AGAANPC1LMNA | |
| SCHEMBL4351854 | 0.79 | ALDH1A1 (0.56) | RAB9AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4351856 | 0.79 | ALDH1A1 (0.56) | RAB9AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL21253031 | 0.79 | MAPT (0.59) | MAPTRAB9AGAANPC1LMNA | |
| SCHEMBL864995 | 0.78 | GAA (0.49) | MAPTRAB9AGAANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NOVARTIS AG (CH) | 2006-04-27 | — | — | US | disclosed |
| EP-1597243-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089365-A1 | Heterocyclic compounds useful as nurr-1 activators | NCOR1, NCOR2, NR4A1 | MAPT 4632/4885RAB9A 2603/4885GAA 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.